Nektar Therapeutics NKTR Income Loss Before Equity Method Investment
Income Loss Before Equity Method Investment at other companies
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept nktr:IncomeLossBeforeEquityMethodInvestment.
The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nektar Therapeutics's income loss before equity method investment.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nektar Therapeutics's income loss before equity method investment?
- Nektar Therapeutics (NKTR) reported income loss before equity method investment of -$43.15M in Q1 2026.
- How has Nektar Therapeutics's income loss before equity method investment changed year-over-year?
- Nektar Therapeutics's income loss before equity method investment increased by 7.0% year-over-year, from -$46.42M to -$43.15M.
- What does income loss before equity method investment mean?
- This metric measures the financial performance of the company's core operations and non-operating activities before accounting for the proportional share of profits or losses from equity-method investments. It serves as a key indicator of the company's standalone profitability and operational health. By excluding equity method results, it isolates the performance of the primary business entity from its strategic partnerships or joint ventures.